SETTING: Concern has been expressed about the bioavailability of rifampicin in some fixed-dose combination (FDC) anti-tuberculosis formulations. OBJECTIVE: To evaluate the relative bioavailability of rifampicin in various FDC formulations currently in use in tuberculosis control programmes in the global market. DESIGN: A two-period randomised crossover bioequivalence study in healthy male volunteers, with a 1 week washout period between treatments. Plasma rifampicin concentrations were measured at 0, 1, 2, 4, 6, 8 and 12 hours after each drug administration. RESULTS: The AUC0-8, AUC0-12 and Cmax for rifampicin in seven of 10 FDC formulations was not found to be bioequivalent to the reference administered as loose (separate) formulations. This was confirmed using parametric and non-parametric statistical methods. CONCLUSIONS: The poor relative bioavailability of rifampicin from some FDCs has been documented. The implications for tuberculosis programmes are extremely serious and warrant urgent attention.
RCT Entities:
SETTING: Concern has been expressed about the bioavailability of rifampicin in some fixed-dose combination (FDC) anti-tuberculosis formulations. OBJECTIVE: To evaluate the relative bioavailability of rifampicin in various FDC formulations currently in use in tuberculosis control programmes in the global market. DESIGN: A two-period randomised crossover bioequivalence study in healthy male volunteers, with a 1 week washout period between treatments. Plasma rifampicin concentrations were measured at 0, 1, 2, 4, 6, 8 and 12 hours after each drug administration. RESULTS: The AUC0-8, AUC0-12 and Cmax for rifampicin in seven of 10 FDC formulations was not found to be bioequivalent to the reference administered as loose (separate) formulations. This was confirmed using parametric and non-parametric statistical methods. CONCLUSIONS: The poor relative bioavailability of rifampicin from some FDCs has been documented. The implications for tuberculosis programmes are extremely serious and warrant urgent attention.
Authors: Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson Journal: Antimicrob Agents Chemother Date: 2008-04-07 Impact factor: 5.191
Authors: Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie Journal: Eur J Clin Pharmacol Date: 2016-06-15 Impact factor: 2.953
Authors: Ana Requena-Méndez; Geraint Davies; Alison Ardrey; Oswaldo Jave; Sonia L López-Romero; Stephen A Ward; David A J Moore Journal: Antimicrob Agents Chemother Date: 2012-02-13 Impact factor: 5.191
Authors: Christine Sekaggya-Wiltshire; Maxwell Chirehwa; Joseph Musaazi; Amrei von Braun; Allan Buzibye; Daniel Muller; Ursula Gutteck; Ilaria Motta; Andrea Calcagno; Jan S Fehr; Andrew Kambugu; Barbara Castelnuovo; Mohammed Lamorde; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero Journal: Clin Infect Dis Date: 2009-06-15 Impact factor: 9.079